Get the Stockscreener App
6.4036
1.06%
0.0736
Verve Therapeutics Inc stock is traded at $6.4036, with a volume of 571.35K.
It is up +1.06% in the last 24 hours and down -14.93% over the past month.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
See More
Previous Close:
$6.33
Open:
$6.35
24h Volume:
571.35K
Relative Volume:
0.38
Market Cap:
$541.65M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-2.4724
EPS:
-2.59
Net Cash Flow:
$-134.39M
1W Performance:
-9.01%
1M Performance:
-14.93%
6M Performance:
+5.21%
1Y Performance:
-60.73%
1-Day Range:
$6.04
$6.4299
1-Week Range:
$5.99
$7.0899
52-Week Range:
$4.305
$16.50
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
6.41 | 541.65M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.74 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.74 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.51 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.14 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada
Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks
Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - Citeline News & Insights
Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha
Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks
Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks
Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK
Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle
Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks
Vertex ends gene editing research pact with Verve - BioPharma Dive
Verve Therapeutics, Inc. SEC 10-K Report - TradingView
Verve Therapeutics: Q4 Earnings Snapshot -February 27, 2025 at 07:33 am EST - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders of Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire
How To Trade (VERV) - Stock Traders Daily
William Blair Reaffirms Outperform Rating for Verve Therapeutics (NASDAQ:VERV) - Defense World
Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday - Defense World
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire
Shareholders that Lost Money on Verve Therapeutics, Inc. (VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Promising Outlook for Verve Therapeutics: Buy Rating Backed by Innovative Treatments and Strategic Partnerships - TipRanks
Optimistic Outlook for Verve Therapeutics Amid Promising Developments and Strategic Partnerships - TipRanks
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Verve Therapeutics, Inc. (VERV) Investigation - ACCESS Newswire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading 10.4% HigherShould You Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Down 4.9%Time to Sell? - MarketBeat
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.7%Time to Buy? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Shares Gap UpHere's What Happened - MarketBeat
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Buy Rating for Verve Therapeutics: VERVE-102’s Enhanced Safety and Promising Efficacy Boost Investor Confidence - TipRanks
Verve Therapeutics Inc [VERV] stock for 3,130 USD was sold by Dorval Allison - Knox Daily
Perhaps timely catching Verve Therapeutics Inc (VERV) would be a good idea - SETE News
Verve Therapeutics (NASDAQ:VERV) Shares Down 5.7%What's Next? - MarketBeat
Verve Investor Drops Class Suit Over Halted Clinical Trial (1) - Bloomberg Law
France Programmatic Ad Seller Quality Rankings Q4 2024: Outbrain Tops Pixalate’s Web Seller Trust Index; Verve No. 1 on Mobile - GlobeNewswire Inc.
STATE STREET CORP Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Verve Therapeutics' Market Cap Up US$69m Following Year Of Insider Stock Buying - Simply Wall St
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):